XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2023
Stock-based Compensation [Abstract]  
Stock-based Compensation
Note 10
Stock-based Compensation:

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of March 31, 2023, there were 3,203,706 shares of common stock remaining available for issuance for awards under the 2016 Plan.
 
The Company measures stock‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded stock‑based compensation expense of $282 and $368 for the three months ended March 31, 2023 and 2022, respectively, within general and administrative expenses in the accompanying condensed consolidated statements of operations. During the three months ended March 31, 2023, the Company also recorded share-based compensation expense of $43 within selling and marketing expenses in the accompanying condensed consolidated statement of operations.

On March 30, 2022, the Company granted 160,000 stock-based options to the Chief Executive Officer. The vesting of these awards is contingent upon meeting one or more financial goals (a performance condition) or a common stock share price (a market condition). The fair value of stock-based awards is determined at the date of grant. Stock-based compensation expense is recorded ratably for market condition awards during the requisite service period and is not reversed, except for forfeitures, at the vesting date regardless of whether the market condition is met. The market condition was not met and 60,000 of the stock-based options were forfeited during 2022. Stock-based compensation expense for performance condition awards is re-evaluated at each reporting period based on the probability of the achievement of the goal.
Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2023:

   
Number of
Shares
   
Weighted Average
Exercise Price
per Share
   
Weighted Average
Remaining
Contractual Term
(in years)
 
Outstanding at January 1, 2023
   
4,474,714
   
$
1.72
       
Granted
   
   
$
       
Exercised
   
 
$
       
Forfeited and expired
   
(10,000
)
 
$
1.45
       
Outstanding at March 31, 2023     4,464,714     $ 1.72       7.8  
Exercisable at March 31, 2023     2,623,841     $ 1.82       7.3  
Vested and expected to vest
    4,464,714     $ 1.72       7.8  

As of March 31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $1,639, which the Company expects to recognize over a weighted‑average period of approximately 2.1 years. The aggregate intrinsic value of options outstanding at March 31, 2023 was $4. There was no aggregate intrinsic value of options exercisable at March 31, 2023.

Restricted Stock Units

Restricted stock units have been issued to certain board members. Restricted stock units unvested are summarized in the following table:

   
Number of
Shares
   
Weighted Average
Grant Date
Fair Value
 
Unvested at January 1, 2023
   
119,597
   
$
0.93
 
Granted
   
   
$
 
Vested
   
(39,866
)
 
$
0.93
 
Unvested at March 31, 2023     79,731     $ 0.93  

As of March 31, 2023, the total unrecognized compensation expense related to unvested restricted stock units was $37, which the Company expects to recognize over a weighted‑average period of approximately 0.3 years.